Caspofungin: First approved agent in a new class of antifungals

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 807-823

  Johnson, Melissa D ^a   Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antifungal agents; Aspergillosis; Candidiasis; Caspofungin; Echinocandin; Mycoses; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CASPOFUNGIN; CILOFUNGIN; CYCLOSPORIN A; DEXAMETHASONE; ECHINOCANDIN B DERIVATIVE; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID; NELFINAVIR; PHENYTOIN; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; RIFAMPICIN; RITONAVIR; TACROLIMUS; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHILL; CLINICAL TRIAL; COCCIDIOIDES IMMITIS; CRYPTOCOCCUS NEOFORMANS; CYSTITIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; ESOPHAGITIS; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HISTOPLASMA CAPSULATUM; HUMAN; HYPOKALEMIA; IN VITRO STUDY; LIVER TOXICITY; MORBIDITY; MORTALITY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHLEBITIS; PYELONEPHRITIS; REVIEW; SALVAGE THERAPY; THROMBOPHLEBITIS; THRUSH; TREATMENT FAILURE; UNITED STATES;

ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ASPERGILLOSIS; BIOLOGICAL AVAILABILITY; CANDIDIASIS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; EXPERT TESTIMONY; FEMALE; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOSES; PEPTIDES; PEPTIDES, CYCLIC; TISSUE DISTRIBUTION;

EID: 0038107441     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.807     Document Type: Review

References (77)

1. Merck & Co. Inc. Cancidas (Injectable formulation) package insert. Merck & Co. Inc., Whitehouse Station, NJ, USA (2001).
2. VAN DUIN D, CASADEVALL A, NOSANCHUK JD: Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob. Agents Chemother. (2002) 46(11):3394-3400.
3. GEORGOPAPADAKOU NH: Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs (2001) 10(2):269-280.
4. POWLES MA, LIBERATOR P, ANDERSON J et al.: Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. (1998) 42(8):1985-1989.
5. GEORGOPAPADAKOU NH, TKACZ JS: The fungal cell wall as a drug target. Trends Microbiol. (1995) 3(3):98-104.
6. KURTZ MB, DOUGLAS CM: Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. (1997) 35(2):79-86.
7. FELDMESSER M, KRESS Y, MEDNICK A, CASADEVALL A: The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. (2000) 182(6):1791-1795.
8. JAMES PG, CHERNIAK R, JONES RG, STORTZ CA, REISS E: Cell wall glucans of Cryptococcus neoformans Cap 67. Carbohydr. Res. (1990) 198(1):23-38.
9. THOMPSON JR, DOUGLAS CM, LI W et al.: A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. (1999) 181(2):444-453.
10. OSHEROV N, MAY GS, ALBERT ND, KONTOYIANNIS DP: Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. (2002) 46(8):2462-2469.
11. KURTZ MB, ABRUZZO G, FLATTERY A et al.: Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. (1996) 64(8):3244-3251.
12. WALDREP TW, KEISER P, WARE A et al.: Failure of intermittent caspofungin therapy to treat fluconazole-resistant mucocutaneous Candida despite apparent in vitro susceptibility. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M-891.
13. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347(25):2020-2029.
14. BARTIZAL K, MOTYL M, HICKS P et al.: In vitro susceptibility results and correlation with outcome: results from the randomized invasive candidiasis study of caspofungin versus amphotericin B. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M-1240.
15. HAJDU R, THOMPSON R, SUNDELOF JG et al.: Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2339-2344.
16. PETRAITIS V, PETRAITIENE R, KELAHER A et al.: Antifungal activity and safety of caspofungin against experimental disseminated candidiasis in persistently neutropenic rabbits. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA (2002) M-188.
17. STONE JA, HOLLAND SD, WICKERSHAM PJ et al.: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. (2002) 46(3):739-745.
18. BALANI SK, XU X, ARISON BH et al.: Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos. (2000) 28(11):1274-1278.
19. STONE JA, HOLLAND SD, LI S et al.: Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001) A-14.
20. STONE JA, BALLOW CH, HOLLAND SD et al.: Single dose caspofungin pharmacokinetics in healthy elderly subjects. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada (2000) 853.
21. STONE JA, MCCREA JB, WICKERSHAM PJ et al.: A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender, and the use of a loading dose regimen. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada (2000) 854.
22. WALSH TJ, ADAMSON PC, SEIBEL NL et al.: Pharmacokinetics of caspofungin in pediatric patients. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M-896.
23. STONE JA, HOLLAND SD, WICKERSHAM PJ et al.: Drug interactions between caspofungin and tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001) A-13.
24. ARATHOON EG, GOTUZZO E, NORIEGA LM et al.: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. (2002) 46(2):451-457.
25. VILLANUEVA A, ARATHOON EG, GOTUZZO E et al.: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. (2001) 33(9):1529-1535.
26. BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2326-2332.
27. ERNST EJ, KLEPSER ME, ERNST ME, MESSER SA, PFALLER MA: In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diag. Microbiol. Infect. Dis. (1999) 33(2):75-80.
28. ABRUZZO GK, FLATTERY AM, GILL CJ et al.: Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococoosis. Antimicrob. Agents Chemother. (1997) 41(11):2333-2338.
29. ABRUZZO GK, GILL CJ, FLATTERY AM et al.: Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. (2000) 44(9):2310-2318.
30. GRAYBILL JR, NAJVAR LK, LUTHER MF, FOTHERGILL AW: Treatment of murine disseminated candidiasis with L-743,872. Antimicrob. Agents Chemother. (1997) 41(8):1775-1777.
31. PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. (2002) 46(1):12-23.
32. ERNST EJ, KLEPSER ME, PFALLER MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44(4):1108-1111.
33. GEISS HK and DILGER S: The post-antifungal effect (PAFE) of caspofungin. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002):A-495.
34. RAMESH MS, BASKARAN I, GANESAN LT, MANAVATHU EK, CHANDRASEKAR PH: Postantifungal effect of older and newer antifungal agents on Aspergillus fumigatus and Candida albicans. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001) J-105.
35. RAMAGE G, VANDEWALLE K, BACHMANN SP, WICKES BL, LOPEZ-RIBOT JL: In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002):M-468.
36. BACHMANN SP, VANDEWALLE K, RAMAGE G et al.: In vitro Interactions between caspofungin and Candida albicans biofilms. In: Program and Abstracts of the 42nd Interscience Conference on AntimicrobialAgents and Chemotherapy, San Diego, CA (2002):M-1512.
37. KUHN DM, GEORGE T, CHANDRA J, MUKHERJEE PK, GHANNOUM MA: Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. (2002) 46(6):1773-1780.
38. KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41(9):1957-1960.
39. FRANZOT SP, CASADEVALL A: Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1997) 41(2):331-336.
40. DEL POETA M, CRUZ MC, CARDENAS ME, PERFECT JR, HEITMAN J: Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44(3):739-746.
41. NELSON PW, LOZANO-CHIU M, REX JH: In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida spp. isolates: influence of assay conditions. J. Med. Vet. Mycol. (1997) 35(4):285-287.
42. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. NCCLS document M27A. National Committee for Clinical Laboratory Standards, Wayne, PA, USA (1997).
43. PFALLER MA, MESSER SA, MILLS K, BOLMSTROM A, JONES RN: Evaluation of E-test method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J. Clin. Microbiol. (2001) 39(12):4387-4389.
44. PFALLER MA, JONES RN, DOERN GV et al.: International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY participant group (Europe). Diag. Microbiol. Infect. Dis. (1999) 35(1):19-25.
45. MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diag. Microbiol. Infect. Dis. (1998) 32(1):33-37.
46. PFALLER MA, MESSER SA, GEE S et al.: In vitro susceptibilities of Candida spp. dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. (1999) 37(3):870-872.
47. BARCHIESI F, SCHIMIZZI AM, FOTHERGILL AW, SCALISE G, RINALDI MG: In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida specics. Eur. J. Clin. Microbiol. Infect. Dis. (1999) 18(4):302-304.
48. ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36(10):2950-2956.
49. GONZALEZ GM, TIJERINA R, NAJVAR LK et al.: Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. (2001) 45(6):1854-1859.
50. ZAAS AK, BOYCE M, SCHELL W, ALEXANDER LODGE BD, PERFECT JR: Rhodotorula fungemia: clinical outcomes and in vitro antifungal susceptibilities. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002):M-900.
51. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard. NCCLS document M-38A. National Committee for Clinical Laboratory Standards, Wayne, PA, USA (2002).
52. HAWSER SP, JESSUP C, VITULLO J, GHANNOUM MA: Utility of 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide (XTT) and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class compounds. J Clin. Microbiol. (2001) 39(7):2738-2741.
53. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. (2001) 45(1):327-330.
54. BEAUVAIS A, BRUNEAU JM, MOL PC et al.: Glucan synthase complex of Aspergillus fumigatus. J. Bacteriol. (2001) 183(7):2273-2279.
55. BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46(9):3001-3012.
56. DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. (1997) 41(8):1835-1836.
57. PFALLER MA. MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diag. Microbiol. Infect. Dis. (1998) 30(4):251-255.
58. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. (2002) 46(1):245-247.
59. PEREA S, GONZALEZ G, FOTHERGILL AW et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. (2002) 46(9):3039-3041.
60. LIU W, LEWIS RE, MAY GS, KONTOYIANNIS DP: Pre-exposure of A. fumigatus to fluconazole induces tolerance to itraconazole in vitro. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M-852.
61. GRAYBILL JR, BOCANEGRA R, LUTHER M, FOTHERGILL A, RINALDI MJ: Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother. (1997) 41(9):1937-1939.
62. JU JY, POLHAMUS C, MARR KA, HOLLAND SM, BENNETT JE: Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/-knockout mice. Antimicrob. Agents Chemother. (2002) 46(5):1240-1245.
63. GRAYBILL JR, NAJVAR LK, MONTALBO EM et al.: Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob. Agents Chemother. (1998) 42(1):151-153.
64. KOHLER S, WHEAT LJ, CONNOLLY P et al.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. (2000) 44(7):1850-1854.
65. BOWMAN JC, ABRUZZO GK, ANDERSON JW et al.: Quantitative PCR assay to measure Aspergillus famigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. (2001) 45(12):3474-3481.
66. KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. (2002) 46(8):2564-2568.
67. VILLANUEVA A, GOTUZZO E, ARATHOON EG et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113(4):294-299.
68. KARTSONIS N, DINUBILE MJ, BARTIZAL K et al.: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune Defic. Syndr. (2002) 31(2):183-187.
69. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Caspofungin versus amphotericin B deoxycholate: in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multi-centre, randomized, double-blind study. In: Program and Abstracts of the 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy (2002):0237.
70. MAERTENS J, RAAD I, PETRIKKOS G et al.: Update of the multicenter noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: analysis of 90 patients. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M-868.
71. KOSS T, BAGHERI B, ZEANA C, ROMAGNOLI MF, GROSSMAN ME: Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J. Amer. Acad. Dermatol. (2002) 46(6):945-947.
72. RUBIN MA, CARROLL KC, CAHILL BC: Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin. Infect. Dis. (2002) 34(8):1160-1161.
73. ALIFF TB, MASLAK PG, JURCIC JG et al.: Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. In: Program and Abstracts of the 43nd Annual Meeting of the American Society of Hematology Orlando, FL, USA (2001):1381.
74. KONTOYIANNIS DP, HACHEM R, LEWIS RE et al.: Efficacy and toxicity of the caspofungin/liposomal amphotericin B combination in documented or possible invasive aspergillosis in patients with hematologic malignancies. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002):M-1820.
75. SAFDAR A: Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin. Infect. Dis. (2002) 34(10):1415-1417.
76. GOODMAN D, PAMER E, JAKUBOWSKI A, MORRIS C, SEPKOWITZ K: Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin. Infect. Dis. (2002) 35(3):E35-E36.
77. STONE JA, MIGOYA E, LI S et al.: Safety and pharmacokinetics of higher doses of caspofungin. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002):A-1319.